🔴 Ultragenyx is trading 47% down today after apazunersen fails Phase 3 Aspire trial

Ultragenyx is trading 47% down at $14.03 after apazunersen (GTX-102) failed its Phase 3 Aspire trial in Angelman syndrome.

• The treatment missed both its primary cognitive endpoint and key secondary MDRI endpoint, with no efficacy difference versus placebo.
• The company is reviewing the program and planning significant expense reductions.
• The biotech sector is higher, making this a company-specific selloff.